FDA proposes new lead limits for baby food to reduce potential risks to children’s health

FDA proposes new lead limits for baby food to reduce potential risks to children’s health


Jgi/jamie Grill | Tetra Images | Getty Images

The Food and Drug Administration proposed new limits Tuesday on lead in baby food, in an effort to reduce exposure to a toxin that can impair childhood development.

The lead limits apply to processed food consumed by children younger than two years old. In a statement, FDA Commissioner Dr. Robert Califf said the limits would reduce lead exposure from these foods by as much as 27%.

related investing news

Cowen says buy Regeneron, success of drugs could help pharmaceutical stock

CNBC Pro

The proposed lead limits are not legally binding on the industry, but the FDA said it would use them as a factor in deciding whether to take enforcement action against a company for selling contaminated food.

The agency proposed the following lead concentration limits for baby food:

  • 10 parts per billion for fruits, vegetables, yoghurts, custards and puddings, mixtures, and single ingredient meats. This would reduce exposure by 26%.
  • 20 parts per billion for root vegetables. This would reduce exposure by 27%.
  • 20 parts per billion for dry cereals. This would reduce exposure by 24%.

Lead is toxic and particularly dangerous for young children. It can impair brain development and the nervous system, resulting in learning disabilities and behavioral difficulties.

Lead exposure through food among children ages 1 to 3 has declined 97% since the 1980s, according to the FDA. Though progress has been made over the years, the agency launched an effort in 2021 to reduce the levels of lead, arsenic, cadmium and mercury in children’s food to the greatest extent possible.

Food consumed by children can contain lead due to contaminated water or soil, industrial activity and old lead-containing equipment used to make food, according to the FDA. The agency said it’s not possible to completely remove lead from the food supply, but the limits should push industry to take measures to reduce its presence as much as possible.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More